Open AccessImmunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer
Author(s) -
Yan Chen,
Zijun Chen,
Rui Chen,
Cheng Fang,
Zun-hua Chu,
Mei Ji,
Xin Yang
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0862
Subject(s) - medicine , osimertinib , lung cancer , immunotherapy , t790m , targeted therapy , oncology , cancer , drug resistance , pd l1 , cancer research , epidermal growth factor receptor , gefitinib , erlotinib , biology , microbiology and biotechnology
The rapid development of molecular targeted therapy brings hope to patients with advanced non-small-cell lung cancer (NSCLC). However, drug resistance inevitably occurs during treatment with EGFR-tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation EGFR-TKI, shows a favorable prognosis in T790M-positive NSCLC. Unfortunately, acquired resistance is still a challenge for both patients and clinicians. There is still no consensus on the optimal treatment. PD-1 and its ligand receptor 1 (PD-L1) inhibitors have yielded great progress, especially in patients with no actionable mutations. In this review, the authors take stock of the relationship between EGFR mutations and PD-L1 expression and summarize the important clinical studies on immunotherapy-inhibitor-based treatment in patients with EGFR-TKI-resistant NSCLC.